drug_type
RELEVANT_DRUG
intervention_type
Monoclonal antibody
drug_description
Anti-CD20 monoclonal antibody that depletes CD20+ B cells via ADCC/CDC, largely sparing long-lived plasma cells, aiming to reduce autoantibody production and downstream inflammation/fibrosis.
nci_thesaurus_concept_id
C1702
nci_thesaurus_preferred_term
Rituximab
nci_thesaurus_definition
A recombinant chimeric murine/human antibody directed against the CD20 antigen, a hydrophobic transmembrane protein located on normal pre-B and mature B lymphocytes. Following binding, rituximab triggers a host cytotoxic immune response against CD20-positive cells. (NCI04)
drug_mesh_term
Rituximab
drug_category
INHIBITORY ANTIBODY
drug_class
Inhibitor
drug_delivery_route
Intravenous
drug_mechanism_of_action
Chimeric anti‑CD20 monoclonal antibody that binds CD20 on pre‑B and mature B cells and depletes them primarily via ADCC and CDC (and apoptosis), reducing naive/memory B cells while largely sparing long‑lived plasma cells; this decreases autoantibody production and downstream inflammatory/fibrotic signaling.
drug_name
rituximab
nct_id_drug_ref
NCT06655896